NASDAQ OMX

Nuvaira Announces Four Clinical Abstracts Accepted for Presentation at ERS International Congress

Dela

Treating COPD and Asthma with Targeted Lung Denervation is Focus of Mini-Symposium

MILAN, Italy, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Nuvaira, a developer of medical devices to treat obstructive lung diseases, today announced that four scientific abstracts featuring the Nuvaira(TM) Lung Denervation System have been accepted for presentation at the upcoming 27th European Respiratory Society (ERS) International Congress, to be held Sept. 9-13, 2017, in Milan, Italy. The abstracts may be viewed through the ERS 2017 website.

Scientific experts will present their findings from studies on the safety and efficacy of Targeted Lung Denervation* (TLD), a bronchoscopic procedure developed to relieve obstructive airway disease, during a Thematic Poster session on "Endoscopic Lung Volume Reduction and TLD" taking place Sunday afternoon, Sept. 10. The abstracts will share some of the important preclinical work on the physiological response to lung denervation as well as clinical work on health related quality-of-life improvements.

In addition, Nuvaira announced it will host an evening mini-symposium at ERS on the use of TLD for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. The program will be co-chaired by Alvar Agustí, M.D., Ph.D., director of the Thorax Institute at Hospital Clinic in Barcelona, and Professor Felix Herth, M.D., Ph.D., FCCP, chairman, Division of Pulmonology and Respiratory Care Medicine, Thoarxklink, at the University of Heidelberg. Five medical experts will present their findings on topics including: Neural Control of Airway Smooth Muscle, TLD Mechanism of Action, the AIRFLOW-1 and AIRFLOW-2 trials on TLD for COPD patients, and the RELIEF-1 trial on TLD for severe asthma patients.

"I am very encouraged by the one-year data from the randomized AIRFLOW-1 Trial of TLD using the Nuvaira Lung Denervation System in patients with COPD," said Dirk-Jan Slebos, M.D., Ph.D., study principal investigator, University Medical Center, Groningen, The Netherlands. "As with earlier feasibility studies, the AIRFLOW-1 data provides strong evidence that TLD is feasible, provides a sustained treatment effect, and has evolved into a safe treatment. I look forward to discussing the findings in further detail during the evening session.

"TLD is the first medical procedure that targets the whole lung by bronchoscopically disrupting overactive parasympathetic nerves to promote airway dilatation and make it easier for patients to breathe. This one-time procedure may provide an important tool for long-term clinical improvement in COPD patients," continued Dr. Slebos.

Nuvaira recently announced completion of patient enrollment in the AIRFLOW-2 trial, the first sham-controlled clinical trial of TLD using the Nuvaira System in patients with moderate to severe COPD. The AIRFLOW-2 (NCT#02058459) trial, designed to assess safety and efficacy of TLD in patients suffering from moderate to severe COPD, has been conducted at 16 institutions throughout Western Europe and includes 82 patients. 

"We are excited to share new outcomes data and to be featured in four clinical abstracts at ERS 2017, the largest meeting of respiratory professionals in the world," said Shane Gleason, chief commercial officer at Nuvaira. "We are equally pleased with the positive feedback from the institutions participating in the AIRFLOW-2 Trial, which will build upon the discoveries and data already collected regarding the treatment of overactive airways nerves during TLD, and the potential to provide lasting, whole-lung improvement."

About COPD
COPD is the umbrella term used to describe a group of diseases such as small airway disease (chronic bronchitis) and emphysema, characterized by chronic and incompletely reversible airway obstruction that interferes with normal breathing. It is estimated that COPD affects 4 to 10 percent of all adults in European countries and more than 300 million people globally1 ,2.

Pharmacological treatment is the approach for most patients today. Inhaled drugs are used once or twice daily to relax and temporarily open airways. Other forms of treatment include pulmonary rehabilitation, oxygen administration and surgical intervention. These treatments provide temporary relief. The annual financial burden of lung disease in Europe is €141 billion and COPD accounts for almost half3. In the United States, COPD costs are estimated to be more than $50 billion annually4.

About Nuvaira
Nuvaira (formerly known as Holaira) is a privately held company headquartered in Minneapolis, Minn. The company is developing the Nuvaira(TM) Lung Denervation System to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves during Targeted Lung Denervation* (TLD). Nuvaira received CE Mark approval for its Nuvaira Lung Denervation System for use during TLD in January 2016. More information may be found at www.Nuvaira.com.

Note to Media : The evening mini-symposium will take place on Sept. 12, at 17:30 in Room Blue 2, MiCo- Milano Congressi.

*Targeted Lung Denervation (TLD) is currently under clinical investigation for chronic obstructive pulmonary disease and is not yet commercially available.

Nuvaira is a trademark of Nuvaira, Inc.

_______________

1 Global Chronic Obstructive Pulmonary Disease Epidemiology and Patient Flow - 2017. Fore Pharma.
2 http://www.efanet.org/get-advice/copd
3 http://www.efanet.org/get-advice/copd
4 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report

Media Inquiries:
Amy Wolter
+1 (763) 450-5676
info@nuvaira.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nuvaira, Inc via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia23.1.2018 04:44Pressmeddelande

TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, an investigational gene therapy for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease. The submission is based on the positive results from the randomized, placebo-controlled phase 3 trial and investigator-led clinical study conducted in Japan. AnGes anticipates being granted conditional approval under the regulatory scheme of "Approval with Conditions and Time Limit" for regenerative medicines. The review process is expected to take approximately one year. HGF plasmid has the potential to be one of the first gene therapy products to be approved for a non-genetic disease with chronic conditions. AnGes grants to Mitsubishi Tan

SEMAFO Inc. : Q4 and Annual 2017 Production and Costs in Line23.1.2018 00:59Pressmeddelande

Boungou 80% Complete - Continues on Time, on Budget MONTREAL, Jan. 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports 2017 production of 206,400 ounces at an all-in sustaining cost of $943 per ounce. As a result, the Corporation has beat its revised production and met its cost guidance for the year. Mana In the fourth quarter, Mana produced 49,500 ounces of gold at a total cash cost1 of $667 per ounce and all-in sustaining cost2 of $987 per ounce Annual production of 206,400 ounces, slightly ahead of 2017 guidance of 190,000 to 205,000 ounces Total cash cost1 for 2017 of $655 per ounce All-in sustaining cost2 for 2017 of $943 per ounce, in line with guidance of $920 to $960 per ounce Gold sales of 205,300 ounces generated 2017 revenues of $259 million ($1,261 per ounce) Mining Operations Mana, Burkina Faso Three-month period Year ended December 31, ended December 31, 2017 2016 Variation 2017 2016 Variation Tonnes processed 653,500 714,200 (8%) 2,739,900 2,753,300 - He

Atico Reports 2017 Fourth Quarter and Full Year Production Results22.1.2018 22:30Pressmeddelande

VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSXV:ATY) (OTC:ATCMF) is pleased to announce operating results for the three and twelve month periods ended December 31, 2017 from its El Roble mine. Production totaled 5.33 million pounds of copper with 2,972 ounces of gold for the fourth quarter ("Q4 2017") and 20.63 million pounds of copper with 10,923 ounces of gold in concentrates for the full year 2017. "Atico has successfully concluded its fourth full year of operating the El Roble mine, exceeding 2017 guidance while achieving the highest annual production results to date," said Fernando E. Ganoza, CEO. "In the upcoming year, we will focus on increasing mineral resources through aggressive exploration at the El Roble mine and the surrounding prospective 6,600 hectare land package, to continue growing production and expanding the operation." Fourth Quarter and Full Year Operational Highlights Fourth Quarter Producti

Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 18:54Pressmeddelande

PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com This announ

Claroty Wins Inaugural S4 ICS Detection Challenge22.1.2018 18:42Pressmeddelande

Product Takes Top Spot in both Asset Discovery and Threat Detection Phases NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Claroty, an innovator in operational technology (OT) network protection, today announced that it was crowned winner of the inaugural S4 ICS Detection Challenge, which took place at the S4x18 Conference in Miami. Claroty's Continuous Threat Detection product claimed top honors in both the Phase I - Identification and Phase II - Detection segments of the challenge. During Phase I, contestants consumed network traffic captured from 15 different sites at an unidentified West Coast (U.S.) oil and gas company. The contestants were required to use their products to identify industrial control system (ICS) assets on the network and provide a view of how the assets were communicating. Contestants were rewarded for discovering assets, identifying specific details about them and were given bonus points for unique insights. Scoring was designed to test the products themselves, rat

CEO optimism booms despite increasing anxiety over threats to growth22.1.2018 18:30Pressmeddelande

· Optimism in global economic growth reaches record level and rises in all countries · US reinforces its lead on China as a target market for growth in 2018 · Over half of CEOs expect their headcount to increase · Terrorism, geopolitical uncertainty, cyber and climate change rise as threats to growth DAVOS, Switzerland, Jan. 22, 2018 (GLOBE NEWSWIRE) -- A record-breaking share of CEOs are optimistic about the economic environment worldwide, at least in the short term. That's one of the key findings of PwC's 21st survey of almost 1,300 CEOs around the world, launched today at the World Economic Forum Annual Meeting in Davos. Fifty seven percent of business leaders say they believe global economic growth will improve in the next 12 months. It's almost twice the level of last year (29%) and the largest ever increase since PwC began asking about global growth in 2012. Optimism in global growth has more than doubled in the US (59%) after a period of uncertainty surrounding the election (201

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum